Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS...
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS...
FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests...
mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire /...
MESA, ARIZONA / ACCESS Newswire / October 9, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), a developer of artificial...
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse...
MESA, ARIZONA / ACCESS Newswire / October 7, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), an emerging innovator in...
MESA, ARIZONA / ACCESS Newswire / October 1, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), an emerging developer of...
Grant supports CHOP's dedication to understanding and treating rare tumors PHILADELPHIA, Sept. 29, 2025 /PRNewswire/ -- Children's Hospital of Philadelphia...
Internationally recognized expert joins to support the organization's commercialization strategy MADISON, Wis., Sept. 25, 2025 /PRNewswire/ -- Elephas Biosciences Corporation...
Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is...
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”),...
The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell...
WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”), a clinical-stage immuno-oncology...
Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for...
FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that...
Registration Link Below for September 30, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - September...
– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need...
MESA, ARIZONA / ACCESS Newswire / September 18, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a leader in AI-powered...
Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762King of Prussia,...
FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that...